News - Eylea

Filter

Current filters:

Eylea

Popular Filters

1 to 25 of 52 results

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Bayer submits marketing authorization for Eylea in Japan

Bayer submits marketing authorization for Eylea in Japan

03-03-2014

US biotech firm Regeneron Pharmaceuticals and partner Bayer’s Japanese subsidiary Bayer Yakuhin have…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneronRegulation

UK’s NICE gives green light to Bayer’s Eylea in final guidance

26-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final guidance…

BayerEyleaNorthern EuropeOphthalmicsPharmaceuticalPricingRegulationUK

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Added benefit of Bayer’s Eylea again not proven, says IQWiG

Added benefit of Bayer’s Eylea again not proven, says IQWiG

08-01-2014

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

BayerEyleaGermanyNorthern EuropeOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE backs second indication for Bayer’s Eylea

UK’s NICE backs second indication for Bayer’s Eylea

31-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today announced that…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

29-11-2013

German drug major Bayer (BAYN: DE) has submitted VEGF Trap-Eye, already marketed under the brand name…

Asia-PacificBayerEyleaOphthalmicsPharmaceuticalRegeneronRegulationUSA

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Eylea filed for EU and US approval in diabetic macular edema

Eylea filed for EU and US approval in diabetic macular edema

07-11-2013

US biotech firm Regeneron Pharmaceuticals says its partner German drug major Bayer has submitted an application…

BayerDiabetesEuropeEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Regeneron reports positive Phase III data for Eylea

Regeneron reports positive Phase III data for Eylea

22-10-2013

Regeneron Pharmaceuticals has announced positive results for Eylea Injection from the Phase III VIBRANT…

EyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronResearch

Bayer’s Eylea primary endpoint in two Phase III trials for DME

Bayer’s Eylea primary endpoint in two Phase III trials for DME

27-09-2013

Bayer (BAYN: DE) this morning said that Eylea has achieved the primary endpoint in two pivotal phase…

BayerEuropeEyleaOpthalmicsPharmaceuticalRegeneronResearch

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Bayer gains new Eylea indication in Europe

29-08-2013

Following a positive recommendation last month from the European Medicines Agency's Medicinal Products…

BayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulation

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

Regeneron revenues leap on Eylea progress

06-08-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares fall 4% to $260 in pre-market…

BayerBiotechnologyEyleaFinancialRegeneron

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

Positive Ph III results for Regeneron/Bayer's Eylea in mCNV

06-06-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany's Bayer (BAYN: DE) have…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

1 to 25 of 52 results

Back to top